A Randomized, Double-blind, Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MET233 in Otherwise Healthy Adult Participants With Obesity or Overweight
Latest Information Update: 01 Jun 2026
At a glance
- Drugs MET 233i (Primary)
- Indications Obesity
- Focus Adverse reactions
- Sponsors Metsera; Pfizer
Most Recent Events
- 26 May 2026 The protocol has been amended to change in treatment arm size and change in interventional study model as Sequential Assignment.
- 26 May 2026 Status changed from active, no longer recruiting to completed.
- 27 Feb 2026 Planned primary completion date changed from 4 Feb 2026 to 15 Apr 2026.